HLI (HLI) investor plans Rule 144 sale of 500 common shares
Rhea-AI Filing Summary
An HLI stockholder has filed a notice under Rule 144 to sell 500 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $87,095.00. The filing notes that 54,515,003 shares of this class of common stock were outstanding at the time of the notice.
The 500 shares were acquired on 05/15/2024 directly from the issuer in an RSA (restricted stock award) transaction, with no separate cash payment described. The Rule 144 notice also repeats the standard representation that the selling holder does not know of any undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- None.
FAQ
What does the HLI Rule 144 filing disclose about planned share sales?
The filing discloses that a stockholder plans to sell 500 shares of HLI common stock under Rule 144, using Morgan Stanley Smith Barney LLC as broker on the NYSE, with an aggregate market value of $87,095.00.
How many HLI shares are outstanding according to this Rule 144 notice?
The notice states that there were 54,515,003 shares of the relevant class of HLI common stock outstanding at the time of the filing.
When and how were the 500 HLI shares being sold under Rule 144 acquired?
The 500 HLI common shares were acquired on 05/15/2024 from the issuer through an RSA (restricted stock award), with the nature of payment shown as N/A.
What is the approximate planned sale date for the HLI shares in this filing?
The filing lists an approximate date of sale of 01/02/2026 for the 500 HLI common shares to be sold on the NYSE.
Which broker is handling the HLI Rule 144 stock sale?
The planned sale of 500 HLI common shares under Rule 144 is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, based at 1 New York Plaza, 8th Floor, New York, NY 10004.
What representation does the selling HLI stockholder make in this Rule 144 notice?
The selling stockholder represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, as required by the form.